REFERENCES
(1) Arigoni, D. Structure of a new type of terpene. Gazz. Chim. Ital. 1962, 92, 884–901.
(2) Birch, A.; Holzapfel, C. W.; Rickards, R. W. The structure and some aspects of the biosynthesis of pleuromutilin. Tetrahedron 1966, 22, 359–387.
(3) Kavanagh, F.; Hervey, A.; Robbins, W. J. Antibiotic substances from basidiomycetes: VIII. pleurotus multilus (Fr.) sacc. and Pleurotus passeckerianus pilat. Proceedings of the National Academy of Sciences of the United States of America 1951, 37, 570–574.
(4) Frank, S.; Paola, F.; Ada, Y.; Jo ̈rg, M.; Harms, S. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol. 2004, 54, 1287–1294.
(5) Davidovich, C.; Bashan, A.; Auerbach, N. T.; Yaggie, R. D.; Gontarek, R. R.; Yonath, A. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl. Acad. Sci. USA 2007, 104, 4291−4296.
(6) Long, K. S.; Hansen, L. H.; Jakobsen, L.; Vester, B. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother. 2006, 50, 1458–1462.
(7) Novak, R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011, 1241, 71–81.
(8) Shang, R. F.; Wang, J. T.; Guo, W. Z.; Liang, J. P. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr. Top. Med. Chem. 2013, 13, 3013–3025.
(9) Tang, Y. Z.; Liu, Y. H.; Chen, J. Y. Pleuromutilin and its derivatives-the lead compounds for novel antibiotics. Mini Reviews in Medicinal Chemistry 2012, 12, 53–61.
(10) Burch, D. G. Tiamulin activity against Brachyspira hyodysenteriae. Vet. Rec. 2008, 163, 760.
(11) Daum, R. S.; Kar, S.; Kirkpatrick, P. Retapamulin. Nature Reviews Drug Discovery 2007, 6, 865–866.
(12) Moody, M. N.; Morrison, L. K.; Tyring, S. K. Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett. 2010, 15, 1−4.
(13) Shang, R. F.; Pu, X. Y.; Xu, X. M.; Xin, Z. J.; Zhang, C.; Guo, W. Z.; Liu, Y.; Liang, J. P. Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors. J. Med. Chem. 2014, 57, 5664–5678.
(14) Lagoja, I. M. Pyrimidine as constituent of natural biologically active compounds. Biodivers 2005, 2, 1–50.
(15) Sheldrick, G. M. SHELXS, Acta Cryst. 2008, A64, 112–122.
(16) Sheldrick, G. M. SHELXL, Acta Cryst. 2008, A64, 112–122.
(17) Cosimelli, B.; Greco, G.; Ehlardo, M.; Novellino, E.; Da Settimo, F.; Taliani, S.; La Motta, C.; Bellandi, M.; Tuccinardi, T.; Martinelli, A.; Ciampi, O.; Trincavelli, M. L.; Martini, C. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J. Med. Chem. 2008, 51, 1764–1770. |